Press release
CINV Treatment Market to Reach USD 3.9 Billion by 2034
CINV Treatment
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49950
Key Takeaways
• Market Size (2024): USD 2.6 billion
• Forecast (2034): USD 3.9 billion
• CAGR (2025 - 2034): 4.1 %
• Leading Companies: Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals), Heron Therapeutics Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Helsinn Healthcare SA, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Ltd., and Mylan N.V.
• Primary Drug Classes: 5-HT3 Receptor Antagonists, NK1 Receptor Antagonists, Corticosteroids, and Cannabinoids.
Market Story
CINV remains one of the most common and distressing side effects of chemotherapy, affecting up to 80 % of oncology patients. Modern treatment protocols emphasize triple-drug regimens combining serotonin, NK1, and dexamethasone agents to achieve superior emesis control.
Pharmaceutical manufacturers are advancing fixed-dose oral combinations, long-acting injectable formulations, and transdermal delivery systems to improve compliance and convenience. Meanwhile, hospitals and cancer centers are integrating AI-driven adherence monitoring and precision-dose scheduling to personalize supportive-care therapy for individual patients.
Market Segmentation
• By Drug Type: 5-HT3 Receptor Antagonists (Ondansetron, Granisetron, Palonosetron) | NK1 Receptor Antagonists (Aprepitant, Fosaprepitant, Netupitant) | Corticosteroids | Others (Cannabinoids & Dopamine Antagonists)
• By Distribution Channel: Hospital Pharmacies | Retail Pharmacies | Online Pharmacies
• By End User: Hospitals | Oncology Clinics | Home-Care Settings
• By Region:
o North America: Dominates with broad drug portfolio and high chemotherapy rates.
o Europe: Focus on patient-centric cancer supportive-care protocols.
o Asia Pacific: Fastest growth driven by rising cancer cases in India and China.
o Latin America & MEA: Improved access to generics and expanded oncology infrastructure.
Explore Full Report here: https://exactitudeconsultancy.com/reports/49950/cinv-treatment-market
Recent Developments
• 2025: Heron Therapeutics launched an extended-release form of Aponvie® for acute and delayed CINV prevention.
• 2024: Novartis introduced a new combination therapy targeting 5-HT3 and NK1 pathways for highly emetogenic chemotherapy.
• 2023: Helsinn Healthcare and Dr. Reddy's partnered to co-market netupitant/palonosetron in emerging markets.
• 2022: Johnson & Johnson initiated clinical trials for an oral multi-receptor antagonist formulation aimed at outpatient CINV management.
Expert Quote
"Supportive oncology care is entering an era of innovation. Long-acting and patient-friendly antiemetics are significantly improving treatment adherence and overall quality of life for chemotherapy patients," said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=49950
Market Drivers
1. Rising Global Cancer Prevalence: Over 19 million new cancer cases annually fuel antiemetic demand.
2. Improved Combination Therapies: Enhanced efficacy through multi-receptor targeting.
3. Patient Adherence and Comfort Focus: Development of oral and transdermal options.
4. Growing Adoption in Emerging Economies: Expansion of oncology infrastructure and generic availability.
Forecast Outlook
Between 2025 and 2034, the CINV treatment landscape will witness integration of digital monitoring tools, AI-assisted dose optimization, and next-generation long-release formulations. Emerging players will focus on affordable, accessible antiemetic solutions for developing markets.
Conclusion
The CINV Treatment Market is evolving with technological innovation and a strong focus on patient well-being. New-age antiemetics and data-driven therapy management are enhancing clinical outcomes and supportive care efficiency for cancer patients globally.
This report is also available in the following languages : Japanese (炎症治療市場), Korean (Cinv 치료 시장), Chinese (癌症治疗市场), French (Marché du traitement Cinv), German (Markt für Cinv-Behandlungen), and Italian (Mercato del trattamento Cinv), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/49950
Related Reports
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market
https://exactitudeconsultancy.com/reports/35075/chemotherapy-induced-nausea-and-vomiting-cinv-drugs-market
Cancer Supportive Care Market
https://exactitudeconsultancy.com/reports/50185/cancer-supportive-care-market
Cancer Biomarkers Market
https://exactitudeconsultancy.com/reports/10897/cancer-biomarkers-market
Cancer Diagnostics Market
https://exactitudeconsultancy.com/reports/10927/cancer-diagnostics-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CINV Treatment Market to Reach USD 3.9 Billion by 2034 here
News-ID: 4265702 • Views: …
More Releases from Exactitude Consultancy
Endodontic Devices Market to Reach USD 3.96 Billion by 2034
Pune, India, November 2025 - A new report published by Exactitude Consultancy reveals that the Global Endodontic Devices Market is valued at USD 2.45 billion in 2024 and is projected to reach USD 3.96 billion by 2034, expanding at a CAGR of 5.1% from 2025 to 2034. The growth is driven by the rising prevalence of dental caries, increasing cosmetic dentistry procedures, and adoption of advanced digital and rotary endodontic…
Stethoscope Market to Surpass USD 810 Million by 2034
Pune, India, November 2025 - According to the latest report from Exactitude Consultancy, the Global Stethoscope Market is valued at USD 530 million in 2024 and is projected to reach USD 810 million by 2034, growing at a steady CAGR of 4.3% from 2025 to 2034. Demand is fueled by advancements in electronic stethoscopes, telemedicine adoption, and the rising prevalence of cardiovascular and respiratory diseases.
Download Full PDF Sample Copy of…
Central Nervous System Biomarkers Market to Reach USD 11.6 Billion by 2034
Pune, India, November 11, 2025 - The global Central Nervous System (CNS) Biomarkers Market is projected to expand from USD 6.9 billion in 2024 to USD 11.6 billion by 2034, growing at a CAGR of 5.4 %, according to Exactitude Consultancy. Surging prevalence of neurological disorders, breakthroughs in liquid biopsy and imaging biomarkers, and growing adoption of AI-powered diagnostics are fueling the demand for CNS biomarker-based testing and research worldwide.
Download…
Ceftiofur Market to Surpass USD 633 Million by 2034
Pune, India, November 11, 2025 - The global Ceftiofur Market is projected to expand from USD 406 million in 2024 to USD 633 million by 2034, growing at a CAGR of 4.5 %, according to Exactitude Consultancy. Rising livestock population, increasing incidence of bacterial respiratory and uterine infections in cattle and swine, and the growing emphasis on veterinary antibiotic stewardship are fueling global demand for ceftiofur formulations.
Download Full PDF Sample…
More Releases for CINV
Emerging Trends Influencing The Growth Of The Chemotherapy-Induced Nausea and Vo …
The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Expected to Be by 2034?
There has been a notable growth in the market size of chemotherapy-induced nausea and vomiting (CINV)…
Key Influencer in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market 202 …
How Are the key drivers contributing to the expansion of the chemotherapy-induced nausea and vomiting (cinv) market?
The escalating cases of cancer are expected to foster the expansion of the market for chemotherapy-induced nausea and vomiting (CINV). This rise is due to the uncontrolled development and spread of cancer cells in the body. As cancer prevalence increases, there's an increased drive to produce highly effective and specific anti-emetic treatments, which would…
Advancements and Trends in the Global Chemotherapy-induced Nausea and Vomiting ( …
Introduction:
The realm of cancer treatment is a dynamic arena where advancements continuously unfold. Among the multitude of challenges that cancer patients face, chemotherapy-induced nausea and vomiting (CINV) is a formidable adversary. In this article, we delve into the intricate landscape of the CINV market, exploring its evolution, current state, and future prospects.
Understanding CINV:
CINV, an acronym that echoes the discomfort experienced by countless individuals, stands for chemotherapy-induced nausea and vomiting. This…
CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the…
CINV Existing and Pipeline Drugs Market : Growing number of patients undergoing …
The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” the business intelligence firm says that…
Global Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs Market Research Re …
This report studies Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
GlaxoSmithKline Plc
Helsinn Group
Heron Therapeutics
Merck & Co Inc
Tesaro
...
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of…
